Experiences with
Rituxan422 public posts
Biosimilars... Not rituxan, but 'highly similar' to rituxan?
Biosimilar --- WHO definition.
'A biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.'
Dr. Sharman... raises some questions...
http://www.cll-nhl.com/2013/06/generic-cancer-drugs-aka-biosimilar.html?m=0#.UcSRmMu9KSM
CLL - a Cancer of the Immune System
temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera, Obinutuzumab/Gazyva or Ofatumumab/Arzerra within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
Want to take advantage of all our features? Just log in!
or
Dr Sharman begins blogging on relevant ASCO papers
"...the progression free survival went from 10 months with chlorambucil to 15 months with rituxan and 23 months with GA-101. To me that indicates that GA-101 is really doing something new / better than the stalwart rituximab."
Infinity Pharmaceuticals to report IPI-145 progress at ASCO 2013
The study is designed to evaluate the safety, pharmacokinetics and clinical activity of IPI-145 in combination with rituxan (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituxan and bendamustine"
"Infinity also announced that IPI-145 has been granted orphan drug designation
Genentech has announced an Expanded Access Program (EAP) for Obinutuzumab (GA101)
Genentech has announced an Expanded Access Program (EAP) for Obinutuzumab (GA101) (next generation Rituxan)
EAPS are used for compassionate reasons ... it is unclear if this will apply outside the U.S.
Biosimilars coming... Rituxan/MabThera patent ending... impact?
This is an interesting overview of Roche and Rituxan/MabThera
'Roche faces its first big test at the end of this year when it loses exclusivity in Europe on MabThera, also known as Rituxan, a treatment for blood cancers and rheumatoid arthritis that had sales of 6.7 billion Swiss francs
Richter's in a Nut Shell
Development of rituximab (Rituxan)-containing intensive chemotherapy regimens and chemo-immunotherapy regimens (eg, R-HyperCVAD [rituximab plus hyperfractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone] or OFAR [oxaliplatin (Eloxatin), fludarabine, and ara-C]) have improved response
Samsung Electronics ... developing Rituxan Biosimilar
Samsung Electronics’ aspirations.... to find a new growth engine in biotechnology ...with their version of Rituxan called SAIT101.
Samsung and 15 other companies are eyeing the 6.5 billion Rituxan market, when patents come off in 2014-15, hoping to mix up their own versions of Rituxan.
Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan
Still to come is data comparing GA101 directly with Rituxan. Roche has said it aims to make the new drug the successor to the older medicine in a bid to defend sales from biosimilar competitors after its patent expires.